SCHEMBL21597735

SCHEMBL21597735

Cc1ccc(C2CC(=O)C2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.41
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
HDAC1 Q13547 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAOB P27338 1/20 0.34
GRM5 P41594 1/20 0.34
MAP1LC3B Q9GZQ8 1/20 0.33
ELANE P08246 1/20 0.33
DGAT1 O75907 1/20 0.33
KDM1A O60341 1/20 0.33
CHRNB2 P17787 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1610503 0.79 TNKS (0.48) TNKSKDM4EGLAHTTKMT2A
SCHEMBL25213052 0.78 PDE4A (0.50) GAAMAPTKDM4EKMT2A
SCHEMBL18590515 0.78 PDE4A (0.50) GAAMAPTKDM4EKMT2A
SCHEMBL31727680 0.77 TNKS (0.40) TNKSGAAMAPTHDAC1HDAC6
SCHEMBL21597671 0.77 KDM1A (0.39) TNKSMAOBKDM1ACHRNB2CHRNA3
SCHEMBL12093737 0.76 KDM4E (0.47) TNKSKDM4EGLAHTTKMT2A
SCHEMBL18929477 0.76 KDM4E (0.51) TNKSKDM4EGLAHTTKMT2A
SCHEMBL11962323 0.74 SMN1; SMN2 (0.54) TNKSMAPTKDM4EGLAHTT
SCHEMBL254836 0.74 CHRNB2 (0.42) TNKSCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL27388761 0.74 SMN1; SMN2 (0.54) TNKSMAPTKDM4EGLAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TNKS 3589/4885GAA 724/4885MAPT 2356/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 TNKS 3589/4885GAA 724/4885MAPT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.